Zhang LH, Liu ST, Zhao Q, Liu XY, Liu T, Zhang Q, Liu MH, Zhao WX. Role of triggering receptor expressed on myeloid cells 2 in the pathogenesis of non-alcoholic fatty liver disease. World J Hepatol 2025; 17(2): 102328 [DOI: 10.4254/wjh.v17.i2.102328]
Corresponding Author of This Article
Wen-Xia Zhao, MD, Chief Physician, Professor, Department of Spleen, Stomach, Liver and Gallbladder Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, No. 19 Renmin Road, Jinshui District, Zhengzhou 450000, Henan Province, China. zhao-wenxia@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Li-Hui Zhang, Su-Tong Liu, Qing Zhao, Xiao-Yan Liu, Tong Liu, Qiang Zhang, Ming-Hao Liu, Department of Spleen, Stomach and Hepatobiliary Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China
Li-Hui Zhang, Su-Tong Liu, Ming-Hao Liu, Wen-Xia Zhao, Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China
Wen-Xia Zhao, Department of Spleen, Stomach, Liver and Gallbladder Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China
Co-first authors: Li-Hui Zhang and Su-Tong Liu.
Author contributions: Zhang LH and Liu ST drafted the manuscript; Zhao Q and Liu XY contributed to literature search; Liu T and Zhang Q organized the references; Liu MH and Zhao WX reviewed and edited the manuscript; all authors have read and approved the final version to be published.
Supported by Henan Province's "Double First-Class" Creation of Scientific Research in Traditional Chinese Medicine, No. HSRP-DFCTCM-2023-7-23 and No. STG-ZYX02-202117; National Traditional Chinese Medicine Clinical Research Base Scientific Research Special Project, No. 2022JDZX098 and No. 2022JDZX114; National Natural Science Foundation of China, No. 82205086; and The 9th China Association for Science and Technology Young Talent Support Project, No. 2023QNRC001.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wen-Xia Zhao, MD, Chief Physician, Professor, Department of Spleen, Stomach, Liver and Gallbladder Diseases, The First Affiliated Hospital of Henan University of Chinese Medicine, No. 19 Renmin Road, Jinshui District, Zhengzhou 450000, Henan Province, China. zhao-wenxia@163.com
Received: October 15, 2024 Revised: January 4, 2025 Accepted: January 18, 2025 Published online: February 27, 2025 Processing time: 128 Days and 1.2 Hours
Core Tip
Core Tip: Triggering receptor expressed on myeloid cells 2 (TREM2) is an immunoglobulin superfamily receptor located on the cell membrane. In the liver, it is mainly expressed on macrophages. TREM2 plays an important regulatory role in lipid metabolism, inflammation, fibrosis, and hepatocellular carcinoma, and is considered a potential therapeutic target for non-alcoholic fatty liver disease (NAFLD) (for example, macrophages with high expression of TREM2 can effectively clear apoptotic liver cells in a timely manner), thereby inhibiting chronic liver inflammation and non-alcoholic steatohepatitis lesions caused by obesity. This article highlights the most recent research developments on TREM2 in NAFLD, in an attempt to identify new pathways for NAFLD treatment.
